CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 980 enrolled
Drug / intervention
Aromasin (exemestane)drug
Likely dose
Aromasin (exemestane) 25mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01050634
NCT01050634N/ACompleted
CompareCT.gov

Sequencing Of Endocrine Therapy In Post-Menopausal Women With Early Breast Cancer (FAST) a Non-interventional Trial With Aromasin®

Pfizer·observational·Posted Jan 15, 2010·Updated Jul 23, 2010

In Brief

An observational study evaluating Aromasin (exemestane) for Post Menopausal Women With Early Breast Cancer. Completed, enrolled 980 participants.

Detailed Summary

Quality of life under therapy with Aromasin® (exemestane) according to IBCSG (International Breast Cancer Study Group) questionnaire. Change of the endometrium after switching from tamoxifen to Aromasin® (exemestane). Deeper knowledge of Adverse Events during routine administration.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsPost Menopausal Women With Early Breast Cancer
Countries--
Collaborators--

Timeline

N/ACompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 15, 2010
Enrollment StartNov 1, 2005
Primary CompletionApr 1, 2009
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 16.5 years ago

Interventions

Aromasin (exemestane)drug

25mg oral tablet, daily, for \>1yr